Extending Rivaroxaban After COVID-19 Hospitalization

Abstract

Patients who are hospitalized with COVID-19 have elevated rates of postdischarge thrombotic events, but uncertainty exists about whether thromboprophylaxis should continue beyond the hospital stay. In a recent phase 3 trial, continuing thromboprophylaxis after patients hospitalized with COVID-19 were discharged reduced major and fatal thromboembolic events without increasing major bleeding.The trial randomized 320 patients hospitalized with COVID-19 at centers in Brazil to 10-mg/d rivaroxaban or no anticoagulation for 35 days after discharge. All patients received thromboprophylaxis while hospitalized and were at high risk of venous thromboembolism at discharge.